100845-83-8
| 中文名称 | 100845-83-8 |
|---|---|
| 中文同义词 | 化合物 T12994 |
| 英文名称 | SQ 28603 |
| 英文同义词 | SQ 28603;3-[[2-(Mercaptomethyl)-1-oxo-3-phenylpropyl]amino]propanoic acid;N-[2-(Mercaptomethyl)-1-oxo-3-phenylpropyl]-β-alanine;β-Alanine, N-[2-(mercaptomethyl)-1-oxo-3-phenylpropyl]-;603;SQ28;3-[(2-benzyl-3-sulfanylpropanoyl)amino]propanoic acid;Squibb 28603 |
| CAS号 | 100845-83-8 |
| 分子式 | C13H17NO3S |
| 分子量 | 267.34 |
| EINECS号 | |
| 相关类别 | |
| Mol文件 | 100845-83-8.mol |
| 结构式 |  |
100845-83-8 性质
| 沸点 | 533.3±50.0 °C(Predicted) |
|---|---|
| 密度 | 1.216±0.06 g/cm3(Predicted) |
| 储存条件 | Store at -20°C |
| 溶解度 | 溶于二甲基亚砜 |
| 酸度系数(pKa) | 4.32±0.10(Predicted) |
NEP
In conscious deoxycorticosterone acetate (DOCA)/salt hypertensive rats, 300 μmol/kg, i.v., of SQ28603 significantly lowers mean arterial pressure (MAP) from 177±12 to 154±8 mm Hg and increases urinary cyclic guanosine monophosphate (GMP) excretion from 204±70 to 1,068±326 pmol/kg/min within 2 h. SQ28603 also significantly reduces NEP activity by 95% in the kidneys (1.28±0.08 vs. 18.35±0.61 μmol/min after SQ28603 and vehicle respectively) and by 77% in the lungs (0.29±0.03 vs. 0.92±0.14 μmol/kg after SQ28603 and vehicle, respectively). In conclusion, inhibition of NEP activity by SQ28603 significantly decreases MAP and increases plasma ANP concentrations and urinary excretion of cyclic GMP in conscious DOCA/salt hypertensive rats. The potent neutral endopeptidase inhibitor SQ28603 significantly increases excretion of sodium from 4.9±2.3 to 14.3±2.1 muequiv./min and cyclic 3',5'-guanosine monophosphate from 118±13 to 179±18 pmol/min after intravenous administration of 300 μmol/kg (approximately 80 mg/kg) in conscious female cynomolgus monkeys.